MedTrace Logo

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

NCT06650488 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-03-20

No results posted yet for this study

Summary

This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.

Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).

If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.

Conditions

  • Staphylococcus Aureus Endocarditis
  • Staphylococcus Aureus Septicemia
  • Staphylococcus Aureus Bloodstream Infection

Interventions

DRUG

Clopidogrel

Patients will change from aspirin to clopidogrel (without loading dose)

DRUG

Aspirin

Patients will continue their existing aspirin.

Sponsors & Collaborators

  • Todd C. Lee MD MPH FIDSA

    lead OTHER

Principal Investigators

  • Todd C Lee, MD MPH FIDSA · Research Institute of the McGill University Health Centre

  • Emily G McDonald, MD MSc · Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06650488 on ClinicalTrials.gov